Q2 FY27 revenue doubles as consolidated profit turns positive
BPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Unaudited Q2 and H1 FY27 results were approved. Consolidated Q2 revenue rose 110.9% year on year to Rs 136.28 crore. Earnings before interest, tax, depreciation and amortisation margin expanded to 17.3% from 1.3%, and profit after tax was Rs 11.82 crore versus a Rs 8.60 crore loss. H1 revenue rose 27.4% and operating cash flow was Rs 83.33 crore. Standalone Q2 profit after tax rose 98.7%, but H1 revenue fell 1.5% and profit fell 28.4%.
Consolidated growth, wider margins and a return to profit support the stock, though standalone H1 weakness and input-cost pressure remain risks.